Dr. Piccart on Metagene Prognostic Signatures

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the development of metagene prognostic signatures for patients with breast cancer.

Piccart is not sure that metagene prognostic signatures can get any better as years have been spent developing what currently exists.

Piccart says there may be one exception in the case of Endopredict. This signature predicts for excellent long-term outcome and disease-free survival at 10 years. Endopredict has been validated in the context of large, randomized, "clean" clinical trials, according to Piccart.